Hepatic findings in long-term clinical trials of ximelagatran (Q36077273)

12 August 2017

1 reference

title

Hepatic findings in long-term clinical trials of ximelagatran (English)

1 reference

12 August 2017

William M Lee

1

1 reference

12 August 2017

Dominique Larrey

2

1 reference

12 August 2017

Rolf Olsson

3

1 reference

12 August 2017

James H Lewis

4

1 reference

12 August 2017

Marianne Keisu

5

1 reference

12 August 2017

Laurent Auclert

6

1 reference

12 August 2017

Sunita Sheth

7

1 reference

12 August 2017

1 January 2005

1 reference

12 August 2017

1 reference

12 August 2017

28

1 reference

12 August 2017

4

1 reference

12 August 2017

351-370

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-200528040-00006

12 August 2017

0 references

cites work

Managing oral anticoagulant therapy

1 reference

12 December 2020

Assessing causality in drug-induced liver injury

1 reference

12 December 2020

Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects

1 reference

12 December 2020

Troglitazone-induced liver failure: a case study

1 reference

12 December 2020

Guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines a

1 reference

12 December 2020

The epidemiology of venous thromboembolism.

1 reference

12 December 2020

Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease

1 reference

12 December 2020

Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.

1 reference

12 December 2020

Causality assessment of adverse reactions to drugs--II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge

1 reference

12 December 2020

Antithrombotic therapy in atrial fibrillation

1 reference

12 December 2020

Drug-induced hepatic disorders. Incidence, management and avoidance

1 reference

12 December 2020

Stroke severity in atrial fibrillation. The Framingham Study

1 reference

12 December 2020

Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial

1 reference

12 December 2020

Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty.

1 reference

12 December 2020

Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study

1 reference

12 December 2020

Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors

1 reference

12 December 2020

Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran

1 reference

12 December 2020

Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial

1 reference

12 December 2020

Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity

1 reference

12 December 2020

The cost-effectiveness of different management strategies for patients on chronic warfarin therapy

1 reference

12 December 2020

Antithrombotic therapy for venous thromboembolic disease

1 reference

12 December 2020

Drug-induced liver disease

1 reference

12 December 2020

Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.

1 reference

12 December 2020

Safety of anticoagulation therapy in well-informed older patients.

1 reference

12 December 2020

Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis

1 reference

12 December 2020

Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.

1 reference

12 December 2020

The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study

1 reference

12 December 2020

Causality assessment versus guilt-by-association in drug hepatotoxicity

1 reference

12 December 2020

Frequency of illness associated with epidemic hepatitis A virus infections in adults

1 reference

12 December 2020

Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial

1 reference

12 December 2020

Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients

1 reference

12 December 2020

Ximelagatran--promises and concerns

1 reference

12 December 2020

Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial

1 reference

12 December 2020

Drug- and chemical-induced cholestasis

1 reference

12 December 2020

Anticoagulants for atrial fibrillation: why is the treatment rate so low?

1 reference

12 December 2020

Epidemiology and individual susceptibility to adverse drug reactions affecting the liver

1 reference

12 December 2020

Criteria of drug-induced liver disorders. Report of an international consensus meeting

1 reference

12 December 2020

Drug-induced hepatotoxicity.

1 reference

12 December 2020

The incidence of bleeding complications associated with warfarin treatment in general practice in the United Kingdom

1 reference

12 December 2020

Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis

1 reference

12 December 2020

The epidemiology of venous thromboembolism in the community

1 reference

12 December 2020

Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range

1 reference

12 December 2020

Why do patients with atrial fibrillation not receive warfarin?

1 reference

12 December 2020

Long-term outcomes after deep venous thrombosis of the lower extremities

1 reference

12 December 2020

Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries

1 reference

12 December 2020

10.2165/00002018-200528040-00006

Identifiers

DOI

1 reference

Dimensions Publication ID

12 August 2017

0 references

1 reference